Impact of a renal drug dosing service on dose adjustment in hospitalized patients with chronic kidney disease

Annals of Pharmacotherapy

Volumn 43, Issue 10, 2009, Pages 1598-1605

  Hassan, Yahaya ^a   Al Ramahi, Rowa J ^a   Aziz, Noorizan Abd ^a   Ghazali, Rozina ^b  

^a SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

^b Penang Adventist Hospital   (Malaysia)

Author keywords

Chronic kidney disease; Dose adjustment; Renal drug dosing service

Indexed keywords

ALLOPURINOL; AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIINFECTIVE AGENT; ATENOLOL; CARDIOVASCULAR AGENT; CEFEPIME; CEFTAZIDIME; CHLOROTHIAZIDE; CILASTATIN PLUS IMIPENEM; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUCONAZOLE; GASTROINTESTINAL AGENT; MEROPENEM; METOCLOPRAMIDE; MINERAL; PIPERACILLIN PLUS TAZOBACTAM; RANITIDINE; SULTAMICILLIN; TRAMADOL;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; CREATININE CLEARANCE; DIALYSIS; DIARRHEA; DOSE CALCULATION; DRUG COST; DRUG INFORMATION; ELECTROLYTE DISTURBANCE; EPIGASTRIC PAIN; FEMALE; HUMAN; HYPOGLYCEMIA; HYPOTENSION; INTERVENTION STUDY; INTESTINAL BLEEDING; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MYALGIA; NEPHROLOGY; NEUTROPENIA; OBSERVATIONAL STUDY; PHARMACIST; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; RESPIRATION DEPRESSION; UNSPECIFIED SIDE EFFECT; VOMITING;

ADULT; AGED; COST SAVINGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COSTS; FEMALE; GUIDELINE ADHERENCE; HOSPITALS, GENERAL; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PATIENT CARE TEAM; PHARMACEUTICAL PREPARATIONS; PHARMACISTS; PHARMACY SERVICE, HOSPITAL; PRACTICE GUIDELINES AS TOPIC; PROFESSIONAL ROLE; PROSPECTIVE STUDIES;

EID: 70449498135     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M187     Document Type: Article

References (43)

1. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients: excessive length of stay, extra cost, and attributable mortality. JAMA 1997;227:301-306
2. Long CL, Raebel MA, Price DW, Magid DJ. Compliance with dosing guidelines in patients with chronic kidney disease. Ann Pharmacother 2004;38:853-858 Epub 30 Mar 2004. DOI 10.1345/aph.1D399
3. Kappel J, Calissi P. Safe drug prescribing for patients with renal insufficiency. Can Med Assoc J 2002;166:473-477 (Pubitemid 34164099)
4. Swan SK, Bennett WM. Drug dosing guidelines in patients with renal failure. West J Med 1992;156:633-638
5. Gabardi S, Abramson S. Drug dosing in chronic kidney disease. Med Clin North Am 2005;89:649-687 (Pubitemid 40332402)
6. Manley HJ, Cannella CA, Bailie GR, Pater WL. Medication-related problems in ambulatory hemodialysis patients: a pooled analysis. Am J Kidney Dis 2005;46:669-680
7. Bonk ME, Krown H, Matuszewski K, Oinonen M. Potentially inappropriate medications in hospitalized senior patients. Am J Health Syst Pharm 2006;63:1161-1165 (Pubitemid 44146112)
8. Fattinger K, Roos M, Vergères P. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol 2000;49:158-167 (Pubitemid 30068294)
9. Fijn R, Van den Bemt PM, Chow M, et al. Hospital prescribing errors: epidemiological assessment of predictors. Br J Clin Pharmacol 2002;53:326-331 (Pubitemid 34226976)
10. Kanjanarat P, Winterstein AG, Johns TE, Hatton RC, Gonzalez-Rothi R. Nature of preventable ADEs in hospitals: a literature review. Am J Health Syst Pharm 2002;60:1750-1759
11. Rommers MK, Teepe-Twiss IM, Guchelaar HG. Preventing adverse drug events in hospital practice: an overview. Pharmacoepidemiol Drug Saf 2007;16:1129-1135 (Pubitemid 350020066)
12. Blix HS, Viktil KK, Moger TA, Reikvam A. Use of renal risk drugs in hospitalized patients with impaired renal function - an underestimated problem. Nephrol Dial Transplant 2006;21:3164-3171 (Pubitemid 44567089)
13. Manley HJ, Drayer DK, Muther RS. Medication-related problem type and appearance rate in ambulatory hemodialysis patients. BMC Nephrol 2003;4:10.
14. Preston SL, Briceland LL, Lomaestro BM, Lesar TS, Bailie GR, Drusano GL. Dosing adjustment of 10 antimicrobials for patients with renal impairment. Ann Pharmacother 1995;29:1202-1207
15. Chertow GM, Lee J, Kumperman GJ, et al. Guided medication dosing for inpatients with renal insufficiency. JAMA 2001;286:2839-2844
16. Pillans PI, Landsberg PG, Fleming AM, Fanning M, Sturtevant MJ. Evaluation of dosage adjustment in patients with renal impairment. Intern Med J 2003;33:10-13 (Pubitemid 36241568)
17. Salomon L, Deray G, Jaudon MC, et al. Medication misuse in hospitalized patients with renal impairment. Int J Qual Health Care 2003;15:331-335 (Pubitemid 36987271)
18. Sweileh WM, Janem SA, Sawalha AF, et al. Medication dosing errors in hospitalized patients with renal impairment: a study in Palestine. Pharmacoepidemiol Drug Saf 2007;16:908-912
19. VanDijk EA, Drabbe NR, Kruijtbosch M, Smet PAD. Drug dosage adjustments according to renal function at hospital discharge. Ann Pharmacother 2006;40:1254-1260 Epub 27 Jun 2006. DOI 10.1345/aph.1G742
20. Leape LL, Bates DW, Cullen DJ, et al. System analysis of adverse drug events. JAMA 1995;274:35-43.
21. Kucukarslan SN, Peters M, Mlynarek MM, Nafziger DA. Pharmacists on rounding teams reduce preventable adverse drug events in hospital general medicine units. Arch Intern Med 2003;163:2014-2018 (Pubitemid 37151242)
22. Falconnier AD, Haefeli WE, Schoenenberger RA, Surber C, Martin- Facklam M. Drug dosage in patients with renal failure optimized by immediate concurrent feedback. J Gen Intern Med 2001;16:369-375 (Pubitemid 34205654)
23. Galanter WL, Didomenico RJ, Polikaitis A. A trial of automated decision support alerts for contraindicated medications using computerized physician order entry. J Am Med Inform Assoc 2005;12:269-274
24. Walton R, Dovey S, Harvey E, Freemantle N. Computer support for determining drug dose: systematic review and meta analysis. Br Med J 1999;318:984-990
25. Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical pharmacists and inpatient medical care: a systematic review. Arch Intern Med 2006;166:955-964
26. Leape LL, Cullen DJ, Clapp MD, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 1999;282:267-270
27. Spruill WJ, Wade WE, Cobb HH. Estimating glomerular filtration rate with a modification of diet in renal disease equation: implications for pharmacy. Am J Health Syst Pharm 2007;64:652-660 (Pubitemid 46481868)
28. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function - measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473-2483 (Pubitemid 43855050)
29. Ashley C, Morlidge C. Introduction to renal therapeutics. London: Pharmaceutical Press, 2008.
30. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 suppl 1):S1-266.
31. Vidal L, Shavit M, Fraser A, Paul M, Leibovici L. Systematic comparison of four sources of drug information regarding adjustment of dose for renal function. Br Med J 2005;331:263-266
32. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med 2004;140:795-801. (Pubitemid 38623529)
33. Nebeker JR, Hurdle JF, Hoffman JM, Roth B, Weir CR, Samore MH. Developing a taxonomy for research in adverse drug events: potholes and signposts. J Am Med Inform Assoc 2002;9(suppl):S80-5.
34. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245
35. Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. N Engl J Med 2003;348:1556-1564 (Pubitemid 36437933)
36. Joy MS, DeHart RM, Gilmartin C, et al. Clinical pharmacists as multidisciplinary health care providers in the management of CKD: a joint opinion by the Nephrology and Ambulatory Care Practice and Research Networks of the American College of Clinical Pharmacy. Am J Kidney Dis 2005;45:1105-1118 (Pubitemid 40806526)
37. Manley HJ, Carroll CA. The clinical and economic impact of pharmaceutical care in end-stage renal disease patients. Semin Dial 2002;15:45-49
38. Kaplan B, Shimp LA, Mason NA, Ascione FJ. Chronic hemodialysis patients. Part II: reducing drug-related problems through application of the focused drug therapy review program. Ann Pharmacother 1994;28:320-324
39. Wang HY, Chan AL, Chen MT, Liao CH. Effect of pharmaceutical care intervention by clinical pharmacists in renal transplant clinics. Transplant Proc 2008;40:2319-2323
40. Grabe DW, Low CL, Bailie GR, Eisele G. Evaluation of drug-related problems in an outpatient hemodialysis unit and the impact of a clinical pharmacist. Clin Nephrol 1997;47:117-121
41. Moffett BS, Mott AR, Nelson DP, Gurwitch KD. Medication dosing and renal insufficiency in a pediatric cardiac intensive care unit: impact of pharmacist consultation. Pediatr Cardiol 2008;29:744-748
42. Leape LL, Cullen DJ, Clapp MD, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 1999;282:267-270
43. Gandhi PJ, Smith BS, Tataronis GR, Maas B. Impact of a pharmacist on drug costs in a coronary care unit. Am J Health Syst Pharm 2001;58:497-503. (Pubitemid 32259720)